Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

Neuronetics, Inc. (NASDAQ: STIM), a leading medical technology company specializing in neurohealth disorders treatment solutions, has announced that it will release its fourth quarter 2024 financial and operating results before the market opens on Tuesday, March 4, 2025. The company will host a conference call to discuss the results at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast in listen-only mode, and telephone participants are encouraged to register and join 10 minutes before the event start.

Neuronetics' strategic vision of transforming lives through exceptional neurohealth therapies has driven its operational and marketing efforts, leading to significant achievements in recent quarters. In the fourth quarter of 2023, the company reported a 12% increase in total revenue compared to the same period in 2022, with U.S. revenue increasing by 13% driven by an increase in NeuroStar treatment session sales. The company's U.S. treatment session revenue per active site also increased to $13,238 in the fourth quarter of 2023, up from $11,500 in the fourth quarter of 2022, indicating a 15.1% improvement in utilization per site.



The company's growth can be attributed to several key drivers, including increased utilization, improving utilization trends, growth in local consumable customers, improving performance at Greenbrook sites, and the launch of the Better Me Guarantee Provider (BMGP) pilot program. The BMGP program, launched in late January 2024, aims to help sites identify more patients in need, ultimately benefiting from treatment using NeuroStar. With 100 customer sites included in the first cohort, the program is on track to expand to over 160 sites by April 2024, potentially driving further growth in treatment session revenue.



Neuronetics' strategic vision has also impacted its marketing efforts, with several healthcare providers updating their policies to reduce the number of antidepressant medication attempts required before TMS treatment eligibility. This change, along with the company's educational initiatives, has contributed to the growth in NeuroStar Advanced Therapy system sales and treatment session revenue.

As Neuronetics prepares to report its fourth quarter 2024 financial and operating results, investors will be looking for continued growth and positive trends in the company's financial performance. The upcoming results will provide valuable insights into the company's progress towards its strategic vision and its potential to transform lives through neurohealth therapies.

In conclusion, Neuronetics' upcoming financial and operating results, along with its strategic vision and operational achievements, will be closely watched by investors and industry observers alike. The company's focus on transforming lives through exceptional neurohealth therapies has driven its growth and success, and the upcoming results will provide a glimpse into the company's future prospects.